Update on Covenant Waiver, Case & Strategic Review

LCM faces mounting financial stress, with more pain likely before any recovery emerges.

What the company is saying

Litigation Capital Management Limited (LCM) is positioning this announcement as a transparent update on its capital structure and risk management, aiming to reassure investors that it is actively addressing recent setbacks. The company highlights the extension of its debt covenant waiver with Northleaf, emphasizing that this extension—now running to 30 June 2026—demonstrates Northleaf’s continued support. Management stresses that the terms of the waiver remain unchanged except for the ongoing 2.00% per annum interest rate increase, and that no additional one-time waiver fee will be charged, subtly framing this as a positive outcome under the circumstances. The announcement openly acknowledges negative developments in two case investments, with a combined invested capital of approximately A$9 million, and signals that material write-downs are expected in the next financial statements. However, the language used to describe these setbacks is vague, with no detail on the nature or magnitude of the losses, nor any discussion of broader portfolio impacts. The company also references the ongoing Strategic Review, first announced on 15 September 2025, but provides no substantive update or timeline, instead promising further information "in due course." The tone is sober and factual, with little attempt at spin, but the communication style is defensive—focusing on process and compliance rather than solutions or future growth. Notable individuals such as Patrick Moloney (CEO) and David Collins (CFO) are named, but their roles are not leveraged to bolster confidence or signal new strategic direction. Overall, the narrative fits a crisis-management playbook: acknowledge problems, stress lender support, and defer substantive answers to a future date. There is no evidence of a shift toward optimism or growth messaging compared to prior communications, and the company’s investor relations strategy appears focused on damage control and regulatory compliance.

What the data suggests

The disclosed numbers are sparse but telling. The only quantified figure is the A$9 million of invested capital at risk across two case investments, which management now expects to write down materially in the next financial statements. This signals a direct hit to asset values and likely to profitability, especially given the absence of any offsetting positive developments. The extension of the debt covenant waiver by one month (from 30 May 2026 to 30 June 2026) is a minor reprieve, but the continued 2.00% per annum interest rate increase indicates that LCM remains under financial pressure and is paying a premium for lender forbearance. There is no disclosure of revenue, profit, cash flow, or even the size of the underlying loan, making it impossible to assess the company’s overall financial health or liquidity position. No historical comparables or period-over-period data are provided, so the trajectory can only be inferred as negative based on the need for a waiver extension and the impending write-downs. Prior targets or guidance are not referenced, and there is no evidence that any have been met. The quality of disclosure is poor: key metrics are missing, and the announcement is structured to minimize transparency about the scale of the company’s challenges. An independent analyst, relying solely on these numbers, would conclude that LCM is in a deteriorating financial position, with near-term losses likely and no clear path to recovery or growth.

Analysis

The announcement is factual and restrained, with no evidence of exaggerated or promotional language. Most claims are realised and relate to the extension of a debt covenant waiver, the terms of the waiver, and the disclosure of negative developments in two investments. Forward-looking statements are limited to management's expectation of material write-downs in the next financial statements and the ongoing nature of the strategic review, both of which are standard disclosures in such contexts. There is no attempt to frame negative news as positive, nor are there aspirational claims about future performance or turnaround. The only capital figure disclosed (A$9 million invested capital at risk) is tied to negative developments, not to new investment or growth. The tone is appropriately cautious given the deteriorating financial situation.

Risk flags

• ●Operational risk is elevated due to negative developments in two case investments, with A$9 million of capital now at risk of write-down. This matters because it directly reduces asset value and signals potential weaknesses in LCM’s underwriting or case selection process.
• ●Financial risk is acute, as evidenced by the need to extend a debt covenant waiver and accept a 2.00% per annum interest rate increase. This suggests LCM is struggling to meet its debt obligations and may face further covenant breaches or liquidity issues.
• ●Disclosure risk is high: the announcement omits key financial metrics such as revenue, profit, cash flow, and the size of the loan, making it difficult for investors to assess the true scale of the company’s problems. The lack of transparency increases uncertainty and undermines confidence.
• ●Pattern-based risk is present, as the company’s communications focus on process (waiver extensions, strategic reviews) rather than substantive solutions or performance improvements. This pattern often precedes further negative surprises.
• ●Timeline/execution risk is significant: the Strategic Review has been ongoing since September 2025 with no concrete outcomes disclosed, and management offers no timeline for resolution. Investors face the risk of prolonged uncertainty and delayed recovery.
• ●Forward-looking risk is material, as the majority of positive claims (e.g., lender support, strategic review progress) are not backed by hard evidence or specific milestones. Investors should be wary of relying on management’s assurances without supporting data.
• ●Capital intensity risk is flagged by the A$9 million invested in just two cases, which have now soured. This concentration risk means that further negative case outcomes could have outsized impacts on LCM’s financial position.
• ●Geographic and regulatory risk is implicit, as the company operates under UK law and is subject to the Market Abuse Regulation (MAR). Any missteps in disclosure or compliance could trigger regulatory scrutiny or penalties, compounding existing challenges.

Bottom line

For investors, this announcement signals that LCM is in a precarious financial position, with immediate losses looming and no clear path to recovery. The extension of the debt covenant waiver buys only a month of breathing room, and the increased interest rate is a tangible cost of ongoing lender anxiety. The expected write-down of A$9 million in invested capital is a material setback, especially given the lack of any positive offsetting news. The company’s narrative is credible in its candor about negative developments, but the absence of detail and the focus on process over outcomes suggest management is still searching for solutions. No notable institutional figures are highlighted as providing new capital or strategic direction, so there is no external validation of a turnaround. To change this assessment, LCM would need to disclose specific, quantified progress on the Strategic Review, demonstrate improved case outcomes, or show evidence of new funding or asset sales. Key metrics to watch in the next reporting period include the actual size of the write-downs, any changes in debt covenants or interest rates, and concrete outcomes from the Strategic Review. At this stage, the information is a clear warning sign rather than a buying opportunity; investors should monitor developments closely but avoid committing new capital until there is evidence of stabilization or recovery. The single most important takeaway is that LCM is in damage-control mode, and the risk of further deterioration remains high.

Announcement summary

(none found in source) Litigation Capital Management Limited announced that the debt covenant waiver from Northleaf that was due to expire on 30 May 2026 has been extended to 30 June 2026. During the extended waiver period, the interest on the loan remains increased by 2.00% per annum consistent with the initial waiver. There is no additional one-time waiver fee in relation to this extension. LCM has recently received negative developments in relation to two of its case investments, which have a combined LCM invested capital of approximately A$9 million. Management expects to recognise material write-downs in relation to these investments in its next set of financial statements. The Strategic Review that was first announced on 15 September 2025 continues to progress. Management will provide an update on the progress of the Strategic Review in due course.

Disagree with this article?